Latest Soligenix News & Updates

See the latest news and media coverage for Soligenix. We track all announcements, press releases, and industry mentions in real time, all in one place.

Soligenix

Late-stage biopharmaceutical company for rare diseases

soligenix.com

Headquarters: Princeton, United States
Founded year: 1987
Company type: Public company
Number of employees: 25–50

Last updated Today

Latest news about Soligenix

In short: Soligenix advanced its clinical portfolio with positive study results for HyBryte and an orphan drug designation for SGX945 in Europe.

Company announcements

May 26 Soligenix

Soligenix notes suitability of its vaccine platform for Bundibugyo virus

The platform could enable rapid development of a thermostable subunit vaccine for the ongoing Ebola outbreak in Congo.

May 8 Soligenix

Soligenix announces Q1 2026 financial results and FLASH2 study halt

Net loss was $2.8 million; cash $6.0 million; FLASH2 trial halted for futility; strategic options including M&A to be evaluated.

April 28 Soligenix

Soligenix announces interim results from Phase 3 FLASH2 trial

The Data Monitoring Committee recommended the study be halted for futility. Soligenix will evaluate strategic options including M&A and advancing dusquetide.

April 2 Soligenix

Soligenix publishes positive HyBryte comparative study results

The head-to-head trial demonstrated a 60% treatment success rate for HyBryte versus 20% for Valchlor, with better tolerability.

Media coverage

Yesterday USA TODAY

Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease

Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet Disease, following a positive recommendation...

May 26 Yahoo Finance

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy

Soligenix shares are also poised to break above the 100-day moving average for the first time in a month, following a four-session rally.

May 14 MSN

Soligenix (SNGX) price target decreased by 60.00% to 6.12

The average one-year price target for Soligenix (NasdaqCM:SNGX) has been revised to $6.12 / share. This is a decrease of 60.00% from the prior estimate...

May 7 AlphaStreet

Soligenix Releases Q1 2026 Financial Results - Alphastreet

Soligenix, Inc. reported a net loss of $2.8M for the first quarter of 2026, translating to a loss of $0.28 per share as the late-stage...

Never miss news about Soligenix

Track Soligenix and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Soligenix competitors & trending companies

Browse news for competitors to Soligenix and other trending companies.